SRDX Quote, Financials, Valuation and Earnings

Atossa Therapeutics, Inc. has a net margin of -17.99% compared to Surmodics, Inc.'s net margin of --. Surmodics, Inc.'s return on equity of -15.45% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.

Surmodics, Inc. has a consensus price target of $43.00, signalling upside risk potential of 0.05%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 611.56%. Given that Atossa Therapeutics, Inc. has higher upside potential than Surmodics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Surmodics, Inc..

Surmodics, Inc. has a beta of 1.338, which suggesting that the stock is 33.829% more volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 0.950, suggesting its less volatile than the S&P 500 by 4.956%.

Surmodics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surmodics, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.

Surmodics, Inc. quarterly revenues are $29.6M, which are larger than Atossa Therapeutics, Inc. quarterly revenues of --. Surmodics, Inc.'s net income of -$5.3M is higher than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Surmodics, Inc.'s price-to-earnings ratio is 35.08x while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surmodics, Inc. is 5.07x versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Celldex Therapeutics, Inc. has a net margin of -17.99% compared to Surmodics, Inc.'s net margin of -7753.43%. Surmodics, Inc.'s return on equity of -15.45% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Surmodics, Inc. has a consensus price target of $43.00, signalling upside risk potential of 0.05%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.14 which suggests that it could grow by 80.45%. Given that Celldex Therapeutics, Inc. has higher upside potential than Surmodics, Inc., analysts believe Celldex Therapeutics, Inc. is more attractive than Surmodics, Inc..

Surmodics, Inc. has a beta of 1.338, which suggesting that the stock is 33.829% more volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.281%.

Surmodics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surmodics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Surmodics, Inc. quarterly revenues are $29.6M, which are larger than Celldex Therapeutics, Inc. quarterly revenues of --. Surmodics, Inc.'s net income of -$5.3M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Surmodics, Inc.'s price-to-earnings ratio is 35.08x while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surmodics, Inc. is 5.07x versus 751.96x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiora Pharmaceuticals, Inc. has a net margin of -17.99% compared to Surmodics, Inc.'s net margin of 84.08%. Surmodics, Inc.'s return on equity of -15.45% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.

Surmodics, Inc. has a consensus price target of $43.00, signalling upside risk potential of 0.05%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 441.87%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Surmodics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Surmodics, Inc..

Surmodics, Inc. has a beta of 1.338, which suggesting that the stock is 33.829% more volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.753, suggesting its less volatile than the S&P 500 by 175.254%.

Surmodics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surmodics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Surmodics, Inc. quarterly revenues are $29.6M, which are larger than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Surmodics, Inc.'s net income of -$5.3M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Surmodics, Inc.'s price-to-earnings ratio is 35.08x while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surmodics, Inc. is 5.07x versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -17.99% compared to Surmodics, Inc.'s net margin of -735.19%. Surmodics, Inc.'s return on equity of -15.45% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Surmodics, Inc. has a consensus price target of $43.00, signalling upside risk potential of 0.05%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 133.42%. Given that Intellia Therapeutics, Inc. has higher upside potential than Surmodics, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Surmodics, Inc..

Surmodics, Inc. has a beta of 1.338, which suggesting that the stock is 33.829% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Surmodics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surmodics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Surmodics, Inc. quarterly revenues are $29.6M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Surmodics, Inc.'s net income of -$5.3M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Surmodics, Inc.'s price-to-earnings ratio is 35.08x while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surmodics, Inc. is 5.07x versus 17.51x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.